Vericel Co. (NASDAQ:VCEL) Insider Sells $304,875.44 in Stock

Vericel Co. (NASDAQ:VCEL) insider Sean C. Flynn sold 6,772 shares of Vericel stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $45.02, for a total transaction of $304,875.44. Following the completion of the sale, the insider now owns 487 shares of the company’s stock, valued at $21,924.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Vericel Trading Up 1.9 %

Shares of NASDAQ VCEL opened at $45.76 on Thursday. The firm has a 50 day moving average of $46.49 and a 200 day moving average of $44.38. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -4,571.43 and a beta of 1.74. Vericel Co. has a 12-month low of $30.18 and a 12-month high of $53.05.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The business had revenue of $51.28 million for the quarter, compared to the consensus estimate of $49.07 million. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. Sell-side analysts predict that Vericel Co. will post 0.11 EPS for the current year.

Hedge Funds Weigh In On Vericel

Several large investors have recently added to or reduced their stakes in VCEL. Congress Asset Management Co. MA lifted its holdings in Vericel by 509.1% during the first quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock valued at $43,514,000 after purchasing an additional 699,147 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in Vericel during the first quarter valued at approximately $12,782,000. Comerica Bank lifted its holdings in Vericel by 61,063.9% during the third quarter. Comerica Bank now owns 208,569 shares of the biotechnology company’s stock valued at $6,991,000 after purchasing an additional 208,228 shares in the last quarter. Geneva Capital Management LLC lifted its holdings in Vericel by 43.6% during the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock valued at $35,330,000 after purchasing an additional 206,202 shares in the last quarter. Finally, FMR LLC lifted its holdings in Vericel by 39.5% during the third quarter. FMR LLC now owns 571,298 shares of the biotechnology company’s stock valued at $19,150,000 after purchasing an additional 161,652 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, June 21st. TD Cowen assumed coverage on shares of Vericel in a research note on Thursday, June 20th. They issued a “buy” rating and a $55.00 price target for the company. Truist Financial reiterated a “buy” rating and issued a $54.00 price target on shares of Vericel in a research note on Tuesday, March 26th. Finally, HC Wainwright boosted their target price on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $48.17.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.